注射用重组人TNK组织型纤溶酶原激活剂用于急性心肌梗死再灌注治疗的效果观察  

Effectiveness of Recombinant Human TNK Tissue-type Fibrinogen Activator for Injection in Reperfusion Therapy of Acute Myocardial Infarction

作　　者：梁熙源 Liang Xiyuan(Department of Emergency Medicine,Guangzhou Baiyun District Zhongluotan Town Health Hospital,Guangzhou 510000,Guangdong Province,China)

机构地区：[1]广州市白云区钟落潭镇卫生院急诊科,广东广州510000

出　　处：《中外医药研究》2024年第23期54-56,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:观察注射用重组人TNK组织型纤溶酶原激活剂用于急性心肌梗死再灌注治疗的效果。方法:选取2021年1月—2024年3月在广州市白云区钟落潭镇卫生院急诊科就诊的急性心肌梗死且需行再灌注治疗的患者60例为观察对象,随机分为对照组与观察组,每组30例。对照组接受肝素及尿激酶治疗,观察组接受注射用重组人TNK组织型纤溶酶原启动剂治疗,比较两组冠状动脉再通率、终点事件发生率、神经损伤情况、日常生活功能、治疗效果。结果:治疗后0.5 h、1 h、2 h,观察组冠状动脉再通率均高于对照组(P<0.05);两组各终点事件发生率及总发生率比较,差异无统计学意义(P>0.05);治疗后,两组美国国家健康研究所卒中量表评分降低,Barthel指数升高,观察组优于对照组(P<0.05);观察组治疗总有效率高于对照组(P=0.044)。结论:注射用重组人TNK组织型纤溶酶原激活剂在急性心肌梗死且需行灌注治疗的患者中的应用效果优于尿激酶与肝素,可提高患者冠状动脉再通率,改善神经损伤和日常生活功能,且未增加终点事件发生率。Objective:To observe the effect of recombinant human TNK tissue-type fibrinogen activator for injection in the reperfusion therapy of acute myocardial infarction.Methods:Sixty patients with acute myocardial infarction requiring reperfusion therapy who attended the Department of Emergency Medicine of Guangzhou Baiyun District Zhongluotan Town Health Hospital from January 2021 to March 2024 were selected for observation,and were randomly divided into the control group and the observation group,with thirty cases in each group.The control group was treated with heparin and urokinase,and the observation group was treated with recombinant human TNK tissue-type fibrinogen initiator for injection.The two groups were compared in terms of coronary revascularization rate,endpoint event rate,nerve damage,daily life function,and treatment effect.Results:0.5 h,1 h and 2 h after treatment,the coronary revascularization rate of the observation group was higher than that of the control group(P<0.05);the comparison of the incidence rate of each endpoint event and the total incidence rate of the two groups,the difference was not statistically significant(P>0.05);after treatment,the score of the stroke scale of the U.S.National Institutes of Health of the two groups was reduced,and the Barthel index was increased,and the observation group was better than that of the control group(P<0.05);the total effective rate of treatment in the observation group was higher than that in the control group(P=0.044).Conclusion:The application of recombinant human TNK tissue-type fibrinogen activator for injection in patients with acute myocardial infarction and needing perfusion therapy is better than urokinase and heparin,which can improve the patients'coronary artery recanalization rate,nerve injury and daily life function without increasing the rate of endpoint events.

关 键 词：急性心肌梗死 再灌注治疗 注射用重组人TNK组织型纤溶酶原激活剂 

分 类 号：R542.22[医药卫生—心血管疾病]